Recently, the official website of the National Medical Products Administration of China (NMPA) showed that the injectable solution of Letermovir developed by Nanjing Zhengda Tianqing, a subsidiary of Sino Biopharm, has obtained marketing approval, making it the first generic drug in the country. Letermovir tablets and injections were first approved for marketing by the FDA in the usa in 2017, under the brand name Prevymis, which is a highly anticipated new drug for cytomegalovirus (CMV). Currently, Letermovir-related formulations have been marketed in nearly 20 countries and regions including the usa, europe, and japan.
正大天晴拿下重磅抗病毒药首仿
Zhengda Tianqing has successfully obtained the first generic antiviral drug.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.